Zepbound 2.5 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 2.5 mg/.5mL

Zepbound contains tirzepatide and acts on incretin pathways involved in metabolic regulation.

• Chronic weight management: Used in adults with obesity, or overweight with at least one weight-related comorbidity, as an adjunct to diet and exercise.
• Obesity treatment support: Helps support weight reduction in eligible adults when prescribed and monitored as part of a broader care plan.
• Overweight with comorbidity: Used in adults with overweight status who also have a weight-related condition that warrants treatment.
• Long-term weight management: Intended for ongoing management of excess body weight when a clinician determines it is appropriate.

• Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating both receptors, it enhances glucose-dependent insulin secretion and lowers glucagon secretion. It also slows gastric emptying and reduces appetite, which contributes to reduced caloric intake and weight loss. Its pharmacologic effects are therefore mediated through combined incretin signaling rather than through insulin replacement.

Zepbound can cause adverse effects that vary in frequency and severity.

Common Side Effects

• Nausea: Frequently reported, especially during treatment initiation or dose changes.
• Diarrhea: May occur and can contribute to fluid loss.
• Vomiting: Can happen in some patients and may worsen dehydration risk.
• Constipation: A commonly reported gastrointestinal effect.
• Abdominal pain: Stomach or abdominal discomfort may occur.
• Decreased appetite: May accompany treatment and contribute to reduced food intake.

Serious or Rare Side Effects

• Pancreatitis: Severe, persistent abdominal pain with or without vomiting requires prompt evaluation.
• Gallbladder problems: Gallstones or inflammation of the gallbladder have been reported.
• Hypoglycemia: Risk increases when used with insulin or insulin secretagogues.
• Kidney injury from dehydration: Can occur if vomiting or diarrhea leads to volume depletion.

Zepbound should be used with standard clinical precautions and product-label guidance.

• Assess suitability: Confirm the indication and review the full medication history before prescribing or dispensing.
• Monitor gastrointestinal tolerance: Nausea, vomiting, diarrhea, and constipation may be clinically significant.
• Watch for pancreatitis symptoms: Persistent severe abdominal pain should be evaluated promptly.
• Review diabetes medicines: Hypoglycemia risk may increase when used with insulin or sulfonylureas.
• Use in pregnancy and breastfeeding: Safety data are limited; clinical decisions should be made by a qualified prescriber.
• Store at 2-8°C: Keep refrigerated, protect from light, and do not freeze or shake.

Tirzepatide may interact with other medicines and can require closer monitoring.

Major Interactions (Avoid)

• Concomitant insulin use: Can raise the risk of clinically important hypoglycemia.
• Sulfonylureas: May also increase hypoglycemia risk when combined.
• Other GLP-1-based therapies: Overlapping pharmacology may increase tolerability concerns without established benefit.

Moderate Interactions (Monitor Closely)

• Oral medicines needing reliable absorption: Slowed gastric emptying may affect absorption timing.
• Antidiabetic agents: Blood glucose should be monitored when therapy is adjusted.
• Drugs sensitive to dehydration: Vomiting or diarrhea may increase adverse-effect risk through fluid loss.